Zavamet 500 Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby aiding in glycemic control without causing significant hypoglycemia. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), leading to increased insulin secretion and decreased glucagon release in a glucose-dependent manner. The synergistic effect of these agents helps achieve better glycemic control in patients inadequately controlled on monotherapy or lifestyle modifications alone. Zavamet 500 is typically administered orally, with dosage individualized based on patient response and tolerability. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Zavamet 500 should be used as part of a comprehensive diabetes management plan, including diet and exercise.